Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

Completed

Conditions studied: Breast Cancer

In brief

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

Key facts

Study ID

NCT01207635

Run by

M.D. Anderson Cancer Center

People needed

42

Starts

2002-11-01

Expected to finish

2006-01-01

Last updated by the study team

2012-07-30

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patient must have a history of breast cancer.
• Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
• Patient must be willing to undergo a duct lavage.
• Patient must sign an Informed Consent.

You may not qualify if…

• None.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.